Mei Pharma Incorporated (NASDAQ:MEIP) on Focus After Report of Less Shorts

February 15, 2018 - By Michael Pereira

 Mei Pharma Incorporated (NASDAQ:MEIP) on Focus After Report of Less Shorts

The stock of Mei Pharma Incorporated (NASDAQ:MEIP) registered a decrease of 39.89% in short interest. MEIP’s total short interest was 66,600 shares in February as published by FINRA. Its down 39.89% from 110,800 shares, reported previously. With 133,300 shares average volume, it will take short sellers 1 days to cover their MEIP’s short positions. The short interest to Mei Pharma Incorporated’s float is 0.2%.

The stock decreased 0.46% or $0.01 during the last trading session, reaching $2.16. About 31,233 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since February 15, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $80.03 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

MEI Pharma, Inc. (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, June 14 by Oppenheimer. The firm earned “Hold” rating on Friday, September 4 by Wedbush. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) rating on Monday, June 26. Oppenheimer has “Buy” rating and $6.5000 target. Oppenheimer maintained it with “Buy” rating and $6.5000 target in Wednesday, May 31 report. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, September 6 report. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) has “Buy” rating given on Wednesday, August 2 by Oppenheimer.

More notable recent MEI Pharma, Inc. (NASDAQ:MEIP) news were published by: Seekingalpha.com which released: “Helsinn Group and MEI Pharma announce that pracinostat has received ODD from …” on January 11, 2018, also Seekingalpha.com with their article: “MEI Pharma’s early-stage study of ME-344 in HER2-negative breast cancer to …” published on February 13, 2018, Prnewswire.com published: “MEI Pharma Reports Second Quarter Fiscal Year 2018 Results” on February 08, 2018. More interesting news about MEI Pharma, Inc. (NASDAQ:MEIP) were released by: Seekingalpha.com and their article: “MEI Pharma: Double Trouble Or Double Double?” published on July 11, 2017 as well as Seekingalpha.com‘s news article titled: “MEI Pharma: A Prime 2018 Turn Around Candidate” with publication date: November 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: